Opko Health Rating Increased to Hold at TheStreet (OPK)
The analysts wrote, “Opko Health (OPK) has been upgraded by TheStreet Ratings from sell to hold. The company’s strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, weak operating cash flow and feeble growth in the company’s earnings per share.”
Shares of Opko Health (NYSE:OPK) traded down 2.49% on Friday, hitting $8.62. 1,921,224 shares of the company’s stock traded hands. Opko Health has a 1-year low of $6.14 and a 1-year high of $12.95. The stock has a 50-day moving average of $8.38 and a 200-day moving average of $8.96. The company’s market cap is $3.567 billion.
Opko Health (NYSE:OPK) last released its earnings data on Friday, May 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.01. The company had revenue of $22.30 million for the quarter, compared to the consensus estimate of $22.77 million. Analysts expect that Opko Health will post $-0.38 EPS for the current fiscal year.
In other Opko Health news, CEO Phillip Md Et Al Frost purchased 10,000 shares of the stock in a transaction dated Wednesday, May 21st. The shares were purchased at an average cost of $8.30 per share, for a total transaction of $83,000.00. Following the transaction, the chief executive officer now directly owns 1,987,500 shares of the company’s stock, valued at approximately $16,496,250. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.
OPK has been the subject of a number of other recent research reports. Analysts at Oppenheimer cut their price target on shares of Opko Health from $13.00 to $12.00 in a research note on Monday, May 12th. They now have an “outperform” rating on the stock. Separately, analysts at Ned Davis Research upgraded shares of Opko Health from a “sell” rating to a “neutral” rating in a research note on Monday, April 28th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $12.50.
OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.